Role of 5-HT2A receptor antagonists in the treatment of insomnia

Nature and Science of Sleep

Volumn 2, Issue , 2010, Pages 139-150

  Vanover, Kimberly E ^a   Davis, Robert E ^b  

^a Intra Cellular Therapies Inc   (United States)

^b 3 D Pharmaceutical Consultants ^*  (United States)

Author keywords

Insomnia; Serotonin; Slow wave sleep; Wake after sleep onset

Indexed keywords

EID: 79251630108     PISSN: None     EISSN: 11791608     Source Type: Journal    
DOI: 10.2147/nss.s6849     Document Type: Review

References (77)

1. Chesson A Jr, Hartse K, Anderson WM, et al. Practice parameters for the evaluation of chronic insomnia. Sleep. 2000;23:1-5.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) American Psychiatric Association: Arlington, VA; 2000.
3. Ancoli-Israel S. Sleep and its disorders in aging populations. Sleep Med. 2009;10:S7-S11.
4. Vitiello MV. Sleep in normal aging. Sleep Med Clin. 2006;1:191-196.
5. Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: A randomized controlled trial. JAMA. 1999;281:991-999. (Pubitemid 29143890)
6. Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW. Cognitive behavior therapy and pharmacotherapy for insomnia: A randomized controlled trial and direct comparison. Arch Intern Med. 2004;164:1888-1896. (Pubitemid 39274359)
7. McClusky HY, Milby JB, Switzer PK, Williams V, Wooten V. Efficacy of behavioral versus triazolam treatment in persistent sleep-onset insomnia. Am J Psychiatry. 1991;148:121-126.
8. Morin CM, Vallières A, Guay B, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: A randomized controlled trial. JAMA. 2009;301:2005-2015.
9. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: A meta-analysis of RCTs. J Gen Intern Med. 2007;22:1335-1350. (Pubitemid 47247294)
10. Walsh JK. Pharmacologic management of insomnia. J Clin Psychiatry. 2004;65(Suppl 16):41-45.
11. Ohayon MM, Reynolds CF 3rd. Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the International Classification of Sleep Disorders (ICSD). Sleep Med. 2009;10:952-960.
12. Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6 weeks of treatment for primary insomnia. Curr Med Res Opin. 2004;20:1979-1991. (Pubitemid 40179637)
13. Scharf M, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: A randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2008;69:1557-1564.
14. Vanover KE, Weiner DM, Makhay M, et al. Pharmacological and behavioral profile of N-(4-fluoropheylmethyl)-N-(1-methylpiperidine- 4-yl)-N'-(4-(2- methylpropyloxy)phenylmethyl) carbamide (2R, 3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine2A receptor inverse agonist. J Pharmacol Exp Ther. 2006;317:910-918.
15. Weiner DM, Burstein ES, Nash N, et al. 5-Hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther. 2001;299:268-276. (Pubitemid 32905144)
16. Rechtschaffen A, Kales AA. A Manual of Standardized Terminology Techniques and Scoring System for Sleep Stage of Human Subjects. Publication 204. Washington, DC: National Institutes of Health, Government Printing Office; 1968.
17. Silber MH, Ancoli-Israel S, Bonnet MH, et al. The visual scoring of sleep in adults. J Clin Sleep Med. 2007;3(2):121-131. (Pubitemid 46649103)
18. Jouvet M. The role of monamine and acetylcholine-containing neurons in the regulation of the sleep-wake cycle. Ergebn Physiol. 1972;64:166-307.
19. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev. 1994;46:157-203. (Pubitemid 24185150)
20. 2A receptors: Molecular biology and mechanisms of regulation. Crit Rev Neurobiol. 1998;12:319-338. (Pubitemid 29073863)
21. Fay R, Kubin L. 5-HT(2A) receptor-like protein is present in small neurons located in rat mesopontine cholinergic nuclei, but absent from cholinergic neurons. Neurosci Lett. 2001;314:77-81. (Pubitemid 33043809)
22. Kocsis B, Varga V, Dahan L, Sik A. Serotonergic neuron diversity: Identification of raphe neurons with discharges time-locked to the hippocampal theta rhythm. Proc Natl Acad Sci U S A. 2006;103: 1059-1064. (Pubitemid 43212221)
23. Rinaldi-Carmona M, Congy C, Pointeau P, Vidal H, Breliere JC, Le Fur G. Identification of binding sites for SR 46349B, A 5-hydroxytryptamine2 receptor antagonist, in rodent brain. Life Sci. 1994;54:119-127.
24. 2A receptors and their mRNA in monkey brain: [3H]MDL100, 907 autoradiography and in situ hybridization studies. J Comp Neurol. 2001;429:571-589. (Pubitemid 32011854)
25. Morilak DA, Garlow SJ, Ciaranello RD. Immunocytochemical localization and description of neurons expressing serotonin2 receptors in the rat brain. Neuroscience. 1993;54:701-717. (Pubitemid 23171330)
26. Piguet P, Galvan M. Transient and long-lasting actions of 5-HT on rat dentate gyrus neurones in vitro. J Physiol. 1994;481:629-639.
27. Shen RY, Andrade R. 5-Hydroxytryptamine2 receptor facilitates GABAergic neurotransmission in rat hippocampus. J Pharmacol Exp Ther. 1998;285:805-812. (Pubitemid 28237465)
28. 2A receptor antagonist. Eur J Pharmacol. 1994;259:137-141. (Pubitemid 24207205)
29. 2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat. Eur J Pharmacol. 2006;553:163-170. (Pubitemid 44794499)
30. 2 antagonist. Mol Pharmacol. 1985;27:600-611. (Pubitemid 15010691)
31. Rinaldi-Carmona M, Congy C, Santucci V, et al. Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist. J Pharmacol Exp Ther. 1992;262:759-768.
32. Ebert B. Discontinued drugs 2007: Central and peripheral nervous system drugs. Expert Opin Invest Drugs. 2009;18:109-123.
33. 4 receptor. Eur J Pharmacol. 1996;24:229-233. (Pubitemid 26378907)
34. Borbély AA, Trachsel L, Tobler I. Effect of ritanserin on sleep stages and sleep EEG in the rat. Eur J Pharmacol. 1988;156:275-278. (Pubitemid 18260489)
35. 2 receptors could be primarily involved in the regulation of slow-wave sleep in the rat. Eur J Pharmacol. 1987; 137:145-146. (Pubitemid 17084723)
36. 2 receptors in the regulation of sleep and wakefulness in the rat. Psychopharmacology. 1989;97:436-442. (Pubitemid 19102542)
37. 2 antagonist ritanserin on sleep-walking cycle in the rat. Pharmacol Biochem Behav. 1992;41:241-243.
38. 2 antagonist ritanserin decreases sleep in cats. Sleep. 1993;16:15-22. (Pubitemid 23024691)
39. Al-Shamma HA, Anderson C, Chuang E, et al. Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia. J Pharmacol Exp Ther. 2010;332:281-290.
40. Stutzmann JM, Eon B, Lucas M, Blanchard JC, Laduron PM. RP 62203, a 5-hydroxytryptamine2 antagonist, enhances deep NREM sleep in rats. Sleep. 1992;15:119-124.
41. 2A receptors. J Neurosci. 2005; 25:11231-11238. (Pubitemid 43083697)
42. 2A receptors. Neuropharmacology. 1994;33:467-471.
43. 6 receptor antagonists promote sleep in rats. Sleep. 2008;31:34-44.
44. Declerck AC, Wauquier A, Van Der Ham-Veltman PHM, Gelders Y. Increase in slow-wave sleep in humans with the serotonin-S2 antagonist ritanserin. The first exploratory polysomnographic sleep study. Curr Ther Res. 1987;41:427-432. (Pubitemid 17065322)
45. Idzikowski C, Mills FJ, Glennard R. 5-Hydroxytryptamine-2 antagonist increases human slow wave sleep. Brain Res. 1986;16:164-168. (Pubitemid 16055814)
46. Idzikowski C, Mills FJ, James J. A dose-response study examining the effects of ritanserin on human slow wave sleep. Br J Clin Pharmacol. 1991;31:193-196.
47. 2 receptor antagonists on slow wave sleep in humans. Psychopharmacology. 1990;101:568-569. (Pubitemid 20220053)
48. Idzikowski C, Cowen PJ, Nutt D, Mills FJ. The effects of chronic ritanserin treatment on sleep and the neuroendocrine response to L-tryptophan. Psychopharmacology. 1987;93:416-420. (Pubitemid 18049578)
49. Landolt H-P, Meier V, Burgess HJ, et al. Serotonin-2 receptors and human sleep: Effect of a selective antagonist on EEG power spectra. Neuropsychopharmacology. 1999;21:455-466. (Pubitemid 29333084)
50. Rosenberg R, Seiden DJ, Hull SG, et al. APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia. Sleep. 2008;31:1663-1671.
51. 2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmacother. 2008;9:3251-3259.
52. 2A receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers. Submitted.
53. Walsh JK, Perlis M, Rosenthal M, Krystal A, Jiang J, Roth T. Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia. J Clin Sleep Med. 2006;2:35-41. (Pubitemid 43325687)
54. 2 receptor blocker, as add-on treatment in narcolepsy. Sleep. 1991;14:130-132.
55. Monti JM, Alterwain P, Estévez F, et al. The effects of ritanserin on mood and sleep in abstinent alcoholic patients. Sleep. 1993;16:647-654. (Pubitemid 23332488)
56. Meltzer HY, Arvanitis L, Bauer D, Rein W; Meta-Trial Study Group. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry. 2004;161:975-984. (Pubitemid 38735983)
57. Adam K, Oswald I. Effects of repeated ritanserin on middle-aged poor sleepers. Psychopharmacology. 1989;99:219-221. (Pubitemid 19215221)
58. Viola AU, Brandenberger G, Toussaint M, Bouhours P, Macher JP, Luthringer R. Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers. Clin Neurophys. 2002;113:429-434. (Pubitemid 34233864)
59. 2 receptor sensitivity in generalised anxiety disorder: A pilot study with ritanserin. Psychopharmacology. 1992;108:387-960.
60. 2 receptor sensitivity in recovered depressed patients. J Affect Disord. 1992;24:177-181.
61. 2 receptor antagonism and slow-wave sleep in major depression. Acta Psychiatr Scand. 1992;86:133-137.
62. Paiva T, Arriaga F, Wauquier A, Lara E, Largo R, Leitao JN. Effects of ritanserin on sleep disturbances of dysthymic patients. Psychopharmacology. 1988;96:395-399.
63. Danjou P, Warot D, Hergueta T, Lacomblez L, Bouhours P, Puech AJ. Comparative study of the psychomotor and antistress effects of ritanserin, alprazolam and diazepam in healthy subjects: Some trait anxiety-independent responses. Int Clin Psychopharmacol. 1992;7: 73-79. (Pubitemid 23009885)
64. Kamali F, Stansfield SC, Ashton CH, Hammond GL, Emanuel MB, Rawlins MD. Absence of withdrawal effects of ritanserin following chronic dosing in healthy volunteers. Psychopharmacology. 1993; 108:213-217.
65. Wiesel FA, Nordström AL, Farde L, Eriksson B. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology. 1994;114:31-38. (Pubitemid 24150517)
66. Johnson BA, Jasinski DR, Galloway GP, et al. Ritanserin in the treatment of alcohol dependence - a multi-center clinical trial. Psychopharmacology. 1996;128:206-215. (Pubitemid 26383308)
67. Vanover KE, Robbins-Weilert D, Wilbraham DG, et al. Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers. J Clin Pharmacol. 2007;47:704-714. (Pubitemid 46800420)
68. 2 antagonists. J Med Chem. 1991;34:2477-2483.
69. 2A antagonist fanaserin in the treatment of schizophrenia. Am J Psychiatry. 1999;156:419-425. (Pubitemid 29124164)
70. Sramek JJ, Kirkesseli S, Paccaly-Moulin A, et al. A bridging study of fananserin in schizophrenic patients. Psychopharmacol Bull. 1998; 34:811-818. (Pubitemid 29497930)
71. Vanover KE, Staner L, Luthringer R, Mates S, Davis RE. ITI-007/ITI-722: A new approach for the treatment of sleep maintenance insomnia and sleep disorders associated with psychiatric and neurological diseases. Sleep. 2009;32:A284.
72. Cohrs S, Meier A, Neumann AC, Jordan W, Rüther E, Rodenbeck A. Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: A randomized, controlled, crossover trial of 12 healthy male subjects. J Clin Psychiatry. 2005; 66:989-996. (Pubitemid 41191790)
73. Sharpley AL, Vassallo CM, Cowen PJ. Olanzapine increases slow-wave sleep: Evidence for blockade of central 5-HT(2C) receptors in vivo. Biol Psychiatry. 2000;47:468-470. (Pubitemid 30110618)
74. Sharpley AL, Attenburrow ME, Hafizi S, Cowen PJ. Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. J Clin Psychiatry. 2005;66:450-454. (Pubitemid 40593573)
75. Dursun SM, Patel JK, Burke JG, Reveley MA. Effects of typical antipsychotic drugs and risperidone on the quality of sleep in patients with schizophrenia: A pilot study. J Psychiatry Neurosci. 1999;24: 333-337.
76. Luthringer R, Staner L, Noel N, et al. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol. 2007;22:299-308. (Pubitemid 47237549)
77. 2A receptor antagonist. Eur J Pharmacol. 2003;25:229-230. (Pubitemid 36929889)